INT59041

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1993
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 17
Total Number 17
Disease Relevance 5.47
Pain Relevance 4.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2E1) oxidoreductase activity (CYP2E1) endoplasmic reticulum (CYP2E1)
enzyme binding (CYP2E1)
Anatomy Link Frequency
liver 1
14.1 1
urine 1
CYP2E1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Paracetamol 146 97.56 Very High Very High Very High
acular 24 92.92 High High
spastic colon 5 88.32 High High
alcohol 35 87.68 High High
cINOD 86 87.40 High High
antagonist 3 84.76 Quite High
Cholecystokinin 2 83.68 Quite High
Dextromethorphan 8 75.00 Quite High
Central nervous system 1 67.16 Quite High
cva 2 65.68 Quite High
Disease Link Frequency Relevance Heat
Suicidal Behaviour 2 99.98 Very High Very High Very High
Toxicity 22 99.92 Very High Very High Very High
Infection 4 99.74 Very High Very High Very High
Cancer 6 97.68 Very High Very High Very High
Apoptosis 6 96.84 Very High Very High Very High
Death 17 96.12 Very High Very High Very High
Alcohol Addiction 4 93.00 High High
Overdose 8 91.40 High High
Functional Bowel Disorder 3 88.32 High High
Injury 32 87.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Watercress has no Importance for the elimination of ethanol by CYP2E1 inhibition.
Negative_regulation (inhibition) of CYP2E1
1) Confidence 0.59 Published 2002 Journal Pharmacol. Toxicol. Section Title Doc Link 12427108 Disease Relevance 0 Pain Relevance 0.10
DASO(2), in addition, is a suicide inhibitor of CYP2E1.
Negative_regulation (inhibitor) of CYP2E1 associated with suicidal behaviour
2) Confidence 0.59 Published 2001 Journal J. Nutr. Section Abstract Doc Link 11238812 Disease Relevance 0.45 Pain Relevance 0.09
Indeed, DAS, DASO and DASO(2) are competitive inhibitors of CYP2E1.
Negative_regulation (inhibitors) of CYP2E1
3) Confidence 0.59 Published 2001 Journal J. Nutr. Section Abstract Doc Link 11238812 Disease Relevance 0.45 Pain Relevance 0.09
Cyp1a2 (E.C. 1.14.14.1) and Cyp2e1 (E.C. 1.14.13.n7) mRNA expression decreased by 3 days post-infection and hepatic Cyp2e1 protein levels were reduced almost 90% at 7 days, when adduct formation was maximally inhibited.
Negative_regulation (reduced) of Cyp2e1 in 14.1 associated with infection
4) Confidence 0.57 Published 2010 Journal Biochem. Pharmacol. Section Abstract Doc Link 20036646 Disease Relevance 1.08 Pain Relevance 1.03
Selective inhibition of CYP3A4 and CYP1A2 did not reduce, whereas the inhibition of CYP2A6 and CYP2E1 significantly decreased NAPQI formation.
Negative_regulation (inhibition) of CYP2E1
5) Confidence 0.57 Published 2002 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 11866476 Disease Relevance 0.24 Pain Relevance 0.39
Renzapride did not inhibit the major CYP drug-metabolizing enzymes CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2E1 or CYP3A4 at concentrations consistent with use in a clinical setting.
Negative_regulation (inhibit) of CYP2E1
6) Confidence 0.51 Published 2008 Journal Drugs R D Section Body Doc Link 18095752 Disease Relevance 0 Pain Relevance 0
In vitro studies using human liver microsomes indicate that fenofibric acid is not an inhibitor of CYP P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
Negative_regulation (inhibitor) of CYP2E1 in liver
7) Confidence 0.46 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922314 Disease Relevance 0 Pain Relevance 0
CYP2E1 polymorphisms may also modulate this condition, although the extent to which 5?
Negative_regulation (polymorphisms) of CYP2E1
8) Confidence 0.43 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1440770 Disease Relevance 0.26 Pain Relevance 0.03
The lambda(max) of the reduced CO difference spectra of both purified rat and human CYP2E1 was found to be 451.5 nm.
Negative_regulation (reduced) of CYP2E1
9) Confidence 0.42 Published 1996 Journal Arch. Biochem. Biophys. Section Abstract Doc Link 8914842 Disease Relevance 0 Pain Relevance 0.08
We conclude that the time course of the interaction with regard to chlorzoxazone elimination and formation is compatible with an inhibition-induction effect of isoniazid on cytochrome P4502E1.
Negative_regulation (inhibition-induction) of cytochrome P4502E1
10) Confidence 0.42 Published 1993 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 8354023 Disease Relevance 0 Pain Relevance 0.35
Furthermore, selective CYP2E1 inhibitors that are used in human therapy were tested for their inhibitory effect on NAPQI formation. 4-Methylpyrazole, disulfiram, and diethyl-dithiocarbamate were the most potent inhibitors with IC(50) values of 50 microM, 8 microM, and 33 microM, respectively.
Negative_regulation (inhibitors) of CYP2E1
11) Confidence 0.42 Published 2002 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 11866476 Disease Relevance 0.24 Pain Relevance 0.39
Pretreatment with YH439, an inhibitor of CYP2E1 gene transcription, markedly reduced CYP2E1 mRNA, protein content, and activity, as well as the rate of AAP-induced JNK activation and cell death.
Negative_regulation (reduced) of CYP2E1 associated with paracetamol and death
12) Confidence 0.41 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11562448 Disease Relevance 0.88 Pain Relevance 0.75
This resulted in >30% inhibition of tolbutamide 4-methyl-hydroxylase (CYP2C9/10) and lauric acid 11-hydroxylase (CYP2E1) activities.
Negative_regulation (inhibition) of CYP2E1
13) Confidence 0.41 Published 2004 Journal Biopharm Drug Dispos Section Abstract Doc Link 15108219 Disease Relevance 0.18 Pain Relevance 0.25
Nonprescription and prescription medication use was documented with specific questioning about ingestion of substances that bind to, induce or inhibit CYP2E1 (e.g. isoniazid, chlorzoxazone, disulfiram).
Negative_regulation (inhibit) of CYP2E1
14) Confidence 0.38 Published 2007 Journal BMC Med Section Body Doc Link PMC1894983 Disease Relevance 0.52 Pain Relevance 0.28
Diethyldithiocarbamate (DDC), a mechanism based CYP2E1 inhibitor, reduced MEM formation at concentrations up to 150 microM between 33 and 43%.
Negative_regulation (inhibitor) of CYP2E1
15) Confidence 0.26 Published 1997 Journal Biopharm Drug Dispos Section Abstract Doc Link 9113345 Disease Relevance 0 Pain Relevance 0.20
Nepafenac is not an inhibitor of the in vitro metabolism of the major cytochrome (CYP) isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) at therapeutic concentrations used in ophthalmic indications (NevanacĀ®).
Negative_regulation (inhibitor) of CYP2E1
16) Confidence 0.22 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693998 Disease Relevance 0.95 Pain Relevance 0.49
Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, CYP2C8, CYP2C19, CYP2D6, CYP2E1, and CYP3A), and the main elimination route of aliskiren is via feces in its unmetabolized form.64 Approximately one-fourth of the absorbed dose also appears in the urine as unchanged compound; the pharmacokinetic and pharmacodynamic differences of aliskiren between Caucasians and Japanese are minimal and no clinically important pharmacokinetic differences were observed between patients with type 2 diabetes and normal population: the half-life of this drug was 40 hours and 44 hours in healthy subjects and patients with diabetes, respectively.58,61


Spec (appears) Negative_regulation (inhibit) of CYP2E1 in urine associated with diabetes mellitus
17) Confidence 0.11 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.23 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox